EnteroMedics (RSLS)
(Delayed Data from NSDQ)
$0.21 USD
-0.01 (-3.44%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.21 0.00 (-1.59%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for ReShape Lifesciences Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 4 | 23 | 4 | 14 |
Receivables | 2 | 2 | 3 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 4 | 3 | 0 | 2 |
Other Current Assets | 0 | 0 | 2 | 4 | 2 |
Total Current Assets | 10 | 10 | 30 | 8 | 18 |
Net Property & Equipment | 0 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 21 | 1 | 0 |
Deposits & Other Assets | 0 | 0 | 1 | 0 | 0 |
Total Assets | 11 | 11 | 54 | 11 | 20 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 3 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 5 | 3 | 0 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 4 | 2 |
Total Current Liabilities | 4 | 7 | 7 | 5 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 1 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4 | 7 | 8 | 6 | 5 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 642 | 628 | 623 | 189 | 188 |
Retained Earnings | -636 | -624 | -577 | -185 | -172 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 7 | 4 | 46 | 5 | 16 |
Total Liabilities & Shareholder's Equity | 11 | 11 | 54 | 11 | 20 |
Total Common Equity | 7 | 4 | 46 | 5 | 16 |
Shares Outstanding | 13.10 | 0.50 | 0.30 | 0.00 | 0.00 |
Book Value Per Share | 0.51 | 7.32 | 153.57 | 4.67 | 15.85 |
Fiscal Year End for ReShape Lifesciences Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2 | 5 | 2 | 5 |
Receivables | NA | 2 | 2 | 2 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 3 | 4 | 3 | 3 |
Other Current Assets | NA | 0 | 0 | 0 | 1 |
Total Current Assets | NA | 8 | 10 | 7 | 11 |
Net Property & Equipment | NA | 0 | 0 | 0 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 8 | 11 | 8 | 12 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 2 | 1 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 4 | 4 | 4 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 4 | 4 | 5 | 5 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 642 | 642 | 637 | 637 |
Retained Earnings | NA | -638 | -636 | -634 | -630 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 5 | 7 | 3 | 7 |
Total Liabilities & Shareholder's Equity | NA | 8 | 11 | 8 | 12 |
Total Common Equity | 0 | 5 | 7 | 3 | 7 |
Shares Outstanding | 13.10 | 13.10 | 13.10 | 3.40 | 2.90 |
Book Value Per Share | 0.00 | 0.35 | 0.51 | 0.91 | 2.32 |